In 2007, Pfizer published a Statement of Defense letter.<ref>{{cite web|url=http://www.pfizer.com/files/news/trovan_statement_defense_summary.pdf |title=Trovan, Kano State Civil Case â€“ Statement Of Defense |format=PDF |accessdate=July 11, 2011}}</ref> The letter states that the drug's oral form was safer and easier to administer, that Trovan had been used safely in over 5000 Americans prior to the Nigerian trial, that mortality in the patients treated by Pfizer was lower than that observed historically in African meningitis epidemics, and that no unusual side effects, unrelated to meningitis, were observed after 4 weeks.
